EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lipocine's enterprise value is $6.42 Mil.
Lipocine's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.85 Mil. Therefore, Lipocine's EV-to-Revenue for today is -2.25.
The historical rank and industry rank for Lipocine's EV-to-Revenue or its related term are showing as below:
LPCN'
s EV-to-Revenue Range Over the Past 10 Years
Min: -185.27 Med: 0.8 Max: 1278.87
Current: -2.25
During the past 13 years, the highest EV-to-Revenue of Lipocine was 1278.87. The lowest was -185.27. And the median was 0.80.
LPCN's EV-to-Revenue is ranked worse than 100% of 1036
companies
in the Biotechnology industry
Industry Median: 7.96
vs LPCN: -2.25
As of today (2024-05-13), Lipocine's stock price is $5.28.
Lipocine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.54. Therefore, Lipocine's PS Ratio for today is .
Lipocine EV-to-Revenue Historical Data
The historical data trend for Lipocine's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lipocine's EV-to-Revenue
For the Biotechnology subindustry, Lipocine's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipocine's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipocine's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Lipocine's EV-to-Revenue falls into.
Lipocine's current Enterprise Value is $6.42 Mil.
Lipocine's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipocine's share price for today is $5.28.
Lipocine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipocine EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Lipocine's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LPCN has been successfully added to your 